Metabolite profiling results for 36 plasma samples collected from nine representative patients of the 15 mg twice daily dose group in a Phase IIb clinical trial
Patients were designated with arbitrary letters to keep anonymous.
| Representative Category | Patient | Center | Day | AZD7325 Concentration (ng/ml) | Metabolites |
|---|---|---|---|---|---|
| No sample below LOQ | X | 03 | 7 | 68.5 | Full profile |
| X | 03 | 14 | 64.5 | Full profile | |
| X | 03 | 21 | 83.3 | Full profile | |
| X | 03 | 28 | 91.1 | Full profile | |
| Y | 05 | 7 | 24.1 | Full profile | |
| Y | 05 | 14 | 31.8 | Full profile | |
| Y | 05 | 21 | 21.0 | Full profile | |
| Y | 05 | 28 | 93.1 | Full profile | |
| Z | 56 | 7 | 80.4 | Full profile | |
| Z | 56 | 14 | 35.0 | Full profile | |
| Z | 56 | 21 | 36.0 | Full profile (see Fig. 5A) | |
| Z | 56 | 28 | 46.0 | Full profile | |
| Some samples below LOQ | R | 14 | 7 | 53.9 | Full profile |
| R | 14 | 14 | 3.0 | Full profile | |
| R | 14 | 21 | Below LOQ | Only M9, M10 and M42 (see Fig. 5B) | |
| R | 14 | 28 | Below LOQ | Only M9, M10 and M42 | |
| S | 49 | 7 | 24.3 | Full profile | |
| S | 49 | 14 | 22.0 | Full profile | |
| S | 49 | 21 | Below LOQ | Only M9, M10 and M42 | |
| S | 49 | 28 | Below LOQ | Only M10 and M42 | |
| T | 20 | 7 | 17.8 | Full profile | |
| T | 20 | 14 | Below LOQ | Only M9, M10, M42, and M46 | |
| T | 20 | 21 | Below LOQ | Only M9, M10, M42, and M46 | |
| T | 20 | 28 | Below LOQ | Only M10, M42, and M46 | |
| All samples below LOQ | U | 16 | 7 | Below LOQ | None |
| U | 16 | 14 | Below LOQ | None | |
| U | 16 | 21 | Below LOQ | None (see Fig. 5C) | |
| U | 16 | 28 | Below LOQ | None | |
| V | 40 | 7 | Below LOQ | None | |
| V | 40 | 14 | Below LOQ | None | |
| V | 40 | 21 | Below LOQ | None | |
| V | 40 | 28 | Below LOQ | None | |
| W | 45 | 7 | Below LOQ | None | |
| W | 45 | 14 | Below LOQ | None | |
| W | 45 | 21 | Below LOQ | None | |
| W | 45 | 28 | Below LOQ | None |
LOQ, limit of quantitation (i.e., 0.5 ng/ml).